Search

Your search keyword '"Stéphane Pillet"' showing total 68 results

Search Constraints

Start Over You searched for: Author "Stéphane Pillet" Remove constraint Author: "Stéphane Pillet"
68 results on '"Stéphane Pillet"'

Search Results

1. Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19

2. Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities

Catalog

Books, media, physical & digital resources

3. Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19

4. Elimination of receptor binding by influenza hemagglutinin improves vaccine-induced immunity

5. Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults.

6. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates

7. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

8. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine

9. Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials

10. Elimination of receptor binding by influenza hemagglutinin improves vaccine-induced immunity

11. Durability and Cross-Reactivity of Immune Responses Induced by an AS03-Adjuvanted Plant-Based Recombinant Virus-Like Particle Vaccine for COVID-19

12. Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge

13. Phase 2 Randomized Trial of an AS03 Adjuvanted Plant-Based Virus-Like Particle Vaccine for Covid-19 in Healthy Adults, Older Adults and Adults with Comorbidities

14. Safety, immunogenicity and protection provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in non-human primates

15. Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants

16. Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro

17. Exposure to lead and vaccine-specific IgG titers in South African children participating in the Venda Health Examination of Mothers, Babies and their Environment (VHEMBE): A longitudinal study

18. Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages

19. A plant-derived VLP influenza vaccine elicits a balanced immune response even in very old mice with co-morbidities

20. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults

21. Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults

22. Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial

24. Integrated antibody and cellular immunity monitoring are required for assessment of the long term protection that will be essential for effective next generation vaccine development

25. The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?

26. A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response

27. Plant-made virus-like particles bearing influenza hemagglutinin (HA) recapitulate early interactions of native influenza virions with human monocytes/macrophages

28. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens

29. Airway Delivery of an Adenovirus-Based Ebola Virus Vaccine Bypasses Existing Immunity to Homologous Adenovirus in Nonhuman Primates

31. Formulaire d'actes de procédure

32. Influenza pathogenesis: Lessons learned from animal studies with H5N1, H1N1 Spanish, and pandemic H1N1 2009 influenza

33. Canine Distemper Virus Selectively Inhibits Apoptosis Progression in Infected Immune Cells

35. Severe seasonal influenza in ferrets correlates with reduced interferon and increased IL-6 induction

36. Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates

37. In Vitro Exposure of Seal Peripheral Blood Leukocytes to Different Metals Reveal a Sex-Dependent Effect of Zinc on Phagocytic Activity

38. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb

39. Effects of polychlorobiphenyls, polybromodiphenylethers, organochlorine pesticides and their metabolites on vitamin A status in lactating grey seals

40. Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates

41. Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies

42. Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets

43. Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents

44. Ferrets as a Model for Morbillivirus Pathogenesis, Complications, and Vaccines

45. Immunomodulatory effects of estradiol and cadmium in adult female rats

46. Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals

47. Sex-specific effects of neonatal exposures to low levels of cadmium through maternal milk on development and immune functions of juvenile and adult rats